Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
Sherief Abd-Elsalam, Shaimaa Soliman, Eslam Saber Esmail, Mai Khalaf, Ehab F Mostafa, Mohammed A Medhat, Ossama Ashraf Ahmed, Mohamed Samir Abd El Ghafar, Mohamed Alboraie, Sahar M Hassany
Biological Trace Element Research, doi:10.1007/s12011-020-02512-1
No specific treatment for COVID-19 infection is available up till now, and there is a great urge for effective treatment to reduce morbidity and mortality during this pandemic. We aimed to evaluate the effect of combining chloroquine/hydroxychloroquine (CQ/HCQ) and zinc in the treatment of COVID-19 patients. This was a randomized clinical trial conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection were randomized into two groups: group I (96) patients received both HCQ and zinc, and group II (95) received HCQ only. The primary endpoints were the recovery within 28 days, the need for mechanical ventilation, and death. The two groups were matched for age and gender. They had no significant difference regarding any of the baseline laboratory parameters or clinical severity grading. Clinical recovery after 28 days was achieved by 79.2% in the zinc group and 77.9% in zinc-free treatment group, without any significant difference (p = 0.969). The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively). The age of the patient and the need for mechanical ventilation were the only risk factors associated with the patients' mortality by the univariate regression analysis (p = 0.001 and < 0.001, respectively). Zinc supplements did not enhance the clinical efficacy of HCQ. More randomized studies are needed to evaluate the value of adding zinc to other therapies for COVID 19. ClinicalTrials.gov Identifier: NCT04447534
Conflict of Interest The authors declare that they have no conflicts of interest.
References
Abd-Elsalam, Esmail, Khalaf, Abdo, Medhat et al., Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study, Am J Trop Med Hyg,
doi:10.4269/ajtmh.20-0873Chan, Yuan, Kok, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet
Channappanavar, Zhao, Perlman, T cell-mediated immune response to respiratory coronaviruses, Immunol Res
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), Zhejiang Da Xue Xue Bao Yi Xue Ban
Dabbagh-Bazarbachi, Clergeaud, Quesada, Zinc ionophore activity of quercetin and epigallocatechin-gallate: from hepa 1-6 cells to a liposome model, J Agric Food Chem
Fiolet, Guihur, Rebeaud, Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and metaanalysis,
doi:10.1016/j.cmi.2020.08.022Frederickson, Koh, Bush, The neurobiology of zinc in health and disease, Nat Rev Neurosci
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Lazarczyk, Favre, Role of Zn2+ ions in host-virus interactions, J Virol
Li, Guan, Wu, Wang, Zhou et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med
Liu, Liao, Qian, Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020, Emerg Infect Dis
Magagnoli, Narendran, Pereira, Outcomes of Hydroxychloroquine usage in United States veterans hospitalized with COVID-19, Med,
doi:10.1016/j.medj.2020.06.001Marjot, Moon, Cook, Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study, J Hepatol,
doi:10.1016/j.jhep.2020.09.024Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with Hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis
Pal, Pawar, Goswami, Sharma, Prasad, Hydroxychloroquine and Covid-19: a cellular and molecular biology based update, Indian J Clin Biochem,
doi:10.1007/s12291-020-00900-xPawar, Pal, Molecular and functional resemblance of dexamethasone and quercetin: a paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients, Phytother Res,
doi:10.1002/ptr.6886Sarin, Choudhury, Lau, Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 liver injury Spectrum study), Hepatol Int,
doi:10.1007/s12072-020-10072-8Shah, Dutta, Shah, Mishra, Role of zinc in severe pneumonia: a randomized double bind placebo controlled study, Ital J Pediatr
Shi, Han, Jiang, Cao, Alwalid et al., Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study, Lancet Infect Dis
Velthuis, Van Den Worm, Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, PLoS Pathog
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Xue, Moyer, Peng, Wu, Hannafon et al., Chloroquine is a zinc ionophore, PLoS One
